Summary Basis for Regulatory Action

First Page		Document Content
Orphan drugs Transfusion medicine Idiopathic thrombocytopenic purpura Romiplostim Thrombocytopenia Intravenous immunoglobulin Rho(D) immune globulin Eltrombopag Platelet Medicine Biology Blood		Summary Basis for Regulatory Action Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 331,47 KB Share Document on Facebook

	Disponible en España romiplostim, primer estimulador de producción de plaquetas sanguíneas Romiplostim representa un importante avance en el tratamiento de la Púrpura Trombocitopénica Inmune (PTI), una rara enfermed DocID: 1sfuy - View Document
	· THROMBOCY TOPENIA · Complement Blockade with C1 Esterase Inhibitor in Refractory Immune Thrombocytopenia Erin Roesch, MD, and Catherine Broome, MD DocID: 1q1KX - View Document
	The UK Paediatric ITP Working Party UK Paediatric Chronic ITP Registry Synopsis DocID: 1g9vS - View Document
	A study of the Implementation of Romiplostim & Eltrombopag in the NHS in England Lisa 1 Cooper DocID: 1fRWP - View Document
	Amgen version datedHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. x DocID: 1aGJl - View Document